{'fraction_non_alphanumeric': 0.053837342497136315, 'fraction_numerical': 0.002290950744558992, 'mean_word_length': 5.67175572519084, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
G-protein &agr;-subunit levels in hippocampus and entorhinal cortex of brains staged for Alzheimer's disease neurofibrillary and amyloid pathologies

G-protein &agr;-subunits (G&agr;o, G&agr;i, G&agr;s, G&agr;q) and adenylyl cyclase (AC) I and II isoforms were quantified in hippocampus and entorhinal cortex from 22 cases staged for Alzheimer's disease (AD) pathologies according to Braak and Braak. Hippocampal G&agr;i levels declined significantly with neurofibrillary staging, whereas AC I levels in this region increased. Significant amyloid stage-related reductions of G&agr;i were seen in both the hippocampus and entorhinal cortex. The hippocampus also showed a significant reduction of G&agr;o with amyloid staging. It is concluded that levels of inhibitory G-protein subunits G&agr;o, and in particular G&agr;i, decrease in parallel to the extent of AD pathology.